The recent published papers and received awards are presented below
2023
J Transl Med. 2023 Nov 27;21(1):857.
Hypoxia-inducible factor 1α modulates interstitial pneumonia-mediated lung cancer progression.Shimoji K, Nakashima T, Masuda T, Namba M, Sakamoto S, Yamaguchi K, Horimasu Y, Mimae T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Okada M, Hattori N.
Sci Rep. 2023 Nov 13;13(1):19729.
Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer.Masuda T, Miura S, Sato Y, Tachihara M, Bessho A, Nakamura A, Miyawaki T, Yoshimine K, Mori M, Shiraishi H, Hamai K, Haratani K, Maeda S, Tabata E, Kitagawa C, Tanizaki J, Imai T, Nogami S, Yamamoto N,
J Pathol. 2023 Oct;261(2):227-237.
Intestinal overgrowth of Candida albicans exacerbates bleomycin-induced pulmonary fibrosis in mice with dysbiosis.Yamada T, Nakashima T, Masuda T, Sakamoto S, Yamaguchi K, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Kamada N, Hattori N.
Cell Commun Signal. 2023 Sep 21;21(1):247.
Nestin and Notch3 collaboratively regulate angiogenesis, collagen production, and endothelial-mesenchymal transition in lung endothelial cells.Daido W, Nakashima T, Masuda T, Sakamoto S, Yamaguchi K, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N.
J Infect Chemother. 2023 Sep;29(9):875-881.
Clinical characteristics of extrapulmonary nontuberculous mycobacteria infections in comparison with pulmonary infections: A single-center, retrospective study in Japan.Omori K, Kitagawa H, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Tadera K, Nomura T, Shigemoto N, Aoki G, Hattori N, Ohge H.
J Allergy Clin Immunol Pract. 2023 Sep;11(9):2792-2800.e2.
Prospective real-world analysis of asthma patients with preserved and reduced physical activity.Iwamoto H, Hirano T, Amano Y, Murakawa K, Fukatsu-Chikumoto A, Yamaji Y, Yamane M, Anabuki K, Otani T, Higaki N, Miyamoto S, Isobe T, Yokoyama A, Matsunaga K, Hattori N.
Respir Med. 2023 Jun:212:107224.
Serum and bronchoalveolar lavage fluid levels of soluble B7H3 in patients with interstitial lung diseases.Nakashima T, Omori K, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N.
Respirology. 2023 Apr;28(4):380-388.
Predictive value of serum high-mobility group box 1 levels for checkpoint inhibitor pneumonitis.Tanahashi H, Yamaguchi K, Kurose K, Nakao S, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Oga T, Oka M, Hattori N.
Sci Rep. 2023 Feb 20;13(1):2988.
Preserved ratio impaired spirometry with or without restrictive spirometric abnormality.Miura S, Iwamoto H, Omori K, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fujitaka K, Hamada H, Yokoyama A, Hattori N.
Cancers (Basel). 2023 Feb 8;15(4):1092.
Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial-Mesenchymal Transition.Tokumo K, Masuda T, Nakashima T, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Okada M, Hamada H, Hattori N.
JTO Clin Res Rep. 2023 Jan 24;4(3):100462.
The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations.Kagawa Y, Hayashida T, Liu J, Mori S, Izumi H, Kumagai S, Udagawa H, Hattori N, Goto K, Kobayashi SS.
2022
Cancers (Basel). 2022 Dec 17;14(24):6236.
Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally Advanced Non-Small-Cell Lung.Daido W, Masuda T, Imano N, Matsumoto N, Hamai K, Iwamoto Y, Takayama Y, Ueno S, Sumii M, Shoda H, Ishikawa N, Yamasaki M, Nishimura Y, Kawase S, Shiota N, Awaya Y, Suzuki T, Kitaguchi S, Fujitaka K, Nagata Y, Hattori N.
Int J Clin Oncol. 2022 Nov;27(11):1698-1705.
Predictive role of circulatory levels of high-mobility group box 1 for radiation pneumonitis in patients with non-small cell lung cancer treated with definitive thoracic radiotherapy.Isoyama S, Yamaguchi K, Imano N, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Nagata Y, Hattori N.
J Asthma Allergy. 2022 Oct 25:15:1539-1547.
Association Between Patient Preference for Inhaler Medications and Asthma Outcomes.Nakanishi Y, Iwamoto H, Miyamoto S, Nakao S, Higaki N, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Matsumoto N, Nakashima T, Onari Y, Fujitaka K, Haruta Y, Hamada H, Hozawa S, Hattori N.
J Clin Med. 2022 Sep 26;11(19):5673.
Hochuekkito Combined with Pulmonary Rehabilitation in Apathetic Patients with Chronic Obstructive Pulmonary Disease: A Randomized Controlled Pilot Trial.Hamada H, Sekikawa K, Okusaki K, Dodo T, Kagawa K, Sumigawa T, Awaya Y, Sakimoto N, Shioya S, Hakozaki K, Kadowaki T, Kakimoto M, Ito R, Kawamichi K, Kondo K, Namba H, Iwamoto H, Hattori N.
Respir Investig. 2022 Jul;60(4):531-542.
Association of the RAGE/RAGE-ligand axis with interstitial lung disease and its acute exacerbation.Yamaguchi K, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fujitaka K, Hamada H, Hattori N.
BMC Pulm Med. 2022 Jun 30;22(1):260.
Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer.Watari N, Yamaguchi K, Terada H, Hamai K, Masuda K, Nishimura Y, Sakamoto S, Masuda T, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Shoda H, Ishikawa N, Fujitaka K, Miyazaki K, Miyata Y, Hamada H, Awai K, Hattori N.
Thorac Cancer. 2022 Jun;13(11):1611-1618.
Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1.Masuda T, Fujitaka K, Suzuki T, Hamai K, Matsumoto N, Matsumura M, Isoyama S, Ueno S, Mito M, Yamaguchi K, Sakamoto S, Kawano R, Masuda K, Nishino R, Ishikawa N, Yamasaki M, Hattori N.
Eur Respir J. 2022 Jan 13;59(1):2100305.
Accelerated decline in lung function in adults with a history of remitted childhood asthma.Miura S, Iwamoto H, Omori K, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fujitaka K, Hamada H, Yokoyama A, Hattori N.
2021
Stem Cell Res Ther. 2021 Sep 16;12(1):506.
Human bone marrow-derived mesenchymal stromal cells cultured in serum-free media demonstrate enhanced antifibrotic abilities via prolonged survival and robust regulatory T cell induction in murine bleomycin-induced pulmonary fibrosis.Takao S, Nakashima T, Masuda T, Namba M, Sakamoto S, Yamaguchi K, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Takahashi S, Nakashima A, Hattori N.
Stem Cell Res Ther. 2021 Aug 23;12(1):471.
Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity.Takahashi H, Nakashima T, Masuda T, Namba M, Sakamoto S, Yamaguchi K, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N.
Cancer Chemother Pharmacol. 2021 Nov;88(5):857-865.
Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease.Otani T, Yamaguchi K, Nakao S, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N.
Orphanet J Rare Dis. 2021 Jul 3;16(1):298.
Quantitative parameters of lymphocyte nuclear morphology in bronchoalveolar lavage fluid as novel biomarkers for sarcoidosis.Horimasu Y, Yamaguchi K, Sakamoto S, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N.
Ann Thorac Surg. 2021 Jun 15:S0003-4975(21)01031-6.
Role of Soluble Receptor for Advanced Glycation End Products in Postoperative Fibrotic Lung Injury.Nakao S, Yamaguchi K, Iwamoto H, Kagimoto A, Mimae T, Tsutani Y, Miyata Y, Hamada H, Okada M, Hattori N.
PLoS One. 2021 Jun 4;16(6):e0252594.
IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis.Nakanishi Y, Horimasu Y, Yamaguchi K, Sakamoto S, Masuda T, Nakashima T, Miyamoto S, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N.
Sci Rep. 2021 May 12;11(1):10105.
Predictive role of circulatory HMGB1 in postoperative acute exacerbation of interstitial lung disease in lung cancer patients.Yamaguchi K, Nakao S, Iwamoto H, Kagimoto A, Handa Y, Sakamoto S, Horimasu Y, Masuda T, Mimae T, Miyamoto S, Nakashima T, Tsutani Y, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N.
Anticancer Res. 2021 May;41(5):2661-2667.
Prognostic Significance of EGFR Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone.Masuda T, Wakabayashi YU, Nakashima T, Nishimura Y, Shimoji K, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Senoo T, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N.
Anticancer Res. 2021 Mar;41(3):1497-1506.
Autoantibody Positivity Is a Risk Factor for Chemotherapy-induced Exacerbation of Interstitial Pneumonia in Lung Cancer.Ito N, Masuda T, Nakashima T, Nakao S, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N.
Am J Clin Pathol. 2021 Sep 8;156(4):644-652.
Analysis of microRNA Expression in Liquid-Based Cytology Samples May Be Useful for Primary Lung Cancer Diagnosis.Araki Y, Arihiro K, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N.
Pulm Pharmacol Ther. 2021 Apr;67:101999.
Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study.Otani T, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Hirata S, Fujitaka K, Hamada H, Sugiyama E, Hattori N.
Medicine (Baltimore). 2021 Feb 19;100(7):e24738
A machine-learning based approach to quantify fine crackles in the diagnosis of interstitial pneumonia: A proof-of-concept study.Horimasu Y, Ohshimo S, Yamaguchi K, Sakamoto S, Masuda T, Nakashima T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Sadamori T, Shime N, Hattori N
Eur J Clin Microbiol Infect Dis. 2021 Apr;40(4):871-877
Concomitant emphysema might increase the false-negative rate of urinary antigen tests in patients with pneumococcal pneumonia: results from a retrospective study.Kobayashi E, Yamaguchi K, Nagaoka R, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Yokozaki M, Ohge H, Hamada H, Hattori N
Cancer Sci. 2021 Jan;112(1):369-379
Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non-small cell lung cancer.Wakabayashi Y, Masuda T, Fujitaka K, Nakashima T, Okumoto J, Shimoji K, Nishimura Y, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Ohshimo S, Hamada H, Hattori N
2020
JAMA Netw Open. 2020 Nov 2;3(11):e2022906
Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers.Shimoji K, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Takeno S, Hide M, Teishima J, Ohdan H, Hattori N
Respir Med. 2020 Oct;172:106131
Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease.Nakao S, Yamaguchi K, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N
Respir Res. 2020 Jun 11;21(1):145
Reduced Endogenous Secretory RAGE in Blood and Bronchoalveolar Lavage Fluid Is Associated With Poor Prognosis in Idiopathic Pulmonary Fibrosis.Yamaguchi K, Iwamoto H, Mazur W, Miura S, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N
J Thorac Dis. 2020 Mar;12(3):1079-1084
Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer.Masuda T, Fujitaka K, Ishikawa N, Nakano K, Yamasaki M, Kitaguchi S, Masuda K, Yamaguchi K, Sakamoto S, Horimasu Y, Kawase S,Miyamoto S, Nakashima T, Iwamoto H, Shiota N, Senoo T, Awaya Y, Kondo T, Yoshida T, Hamada H, Murakami I, Hattori N
Int J Clin Oncol. 2020 Jan;25(1):74-81
Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer.Nakanishi Y, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Mimae T, Nakashima T, Miyamoto S, Tsutani Y, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N
Respirology. 2020 Mar;25(3):275-280
Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis.Yamaguchi K, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N
2019
Am J Respir Crit Care Med. 2019 Oct 15;200(8):1032-1044
Role of B7H3/IL-33 Signaling in Pulmonary Fibrosis-induced Profibrogenic Alterations in Bone Marrow.Nakashima T, Liu T, Hu B, Wu Z, Ullenbruch M, Omori K, Ding L, Hattori N, Phan SH
J Clin Med. 2019 Nov 24;8(12)
Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis: German and Japanese Cohort Study.Hirano C, Ohshimo S, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, Kohno N, Komoto D, Awai K, Shime N, Bonella F, Guzman J, Kühl H, Costabel U, Hattori N
Anticancer Res. 2019 Oct;39(10):5725-5731
Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer.Nakao S, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N
Respiration. 2019;98(3):212-220
C-C Motif Chemokine Ligand 15 May Be a Useful Biomarker for Predicting the Prognosis of Patients with Chronic Hypersensitivity Pneumonitis.Watanabe M, Horimasu Y, Iwamoto H, Yamaguchi K, Sakamoto S, Masuda T, Nakashima T, Miyamoto S, Ohshimo S, Fujitaka K, Hamada H, Kohno N, Hattori N
Respir Investig. 2019 Sep;57(5):451-459
Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.Nakanishi Y, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Tsutani Y, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N
Respir Med. 2019 Jun;152:44-50
Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia.Shioya S, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Senoo T, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N
Free Radic Biol Med. 2019 May 20;136:52-59
Suplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stress.Izumi Y, Nakashima T, Masuda T, Shioya S, Fukuhara K, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N
J Cell Mol Med. 2019 Apr;23(4):2984-2994
Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts.Masuda T, Nakashima T, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N
Medicine (Baltimore). 2019 Feb;98(5):e14296
High preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgery.Takao S, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N
Intern Med. 2019 Apr 1;58(7):915-920
Performance Status Is a Risk Factor for Depression before the Diagnosis of Lung Cancer Patients.Miwata K, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N
2018
Exp Ther Med. 2018 Dec;16(6):5236-5242
Effects of Hochuekkito combined with pulmonary rehabilitation in patients with chronic obstructive pulmonary disease.Hamada H, Sekikawa K, Murakami I, Aimoto K, Kagawa K, Sumigawa T, Okusaki K, Dodo T, Awaya Y, Watanabe M, Kondo K, Ogawa T, Yamamoto H, Hattori N
Medicine (Baltimore). 2018;97:e13542
Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody: A retrospective cohort study.Yamaguchi K, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Kohno N, Hattori N
Cancer Lett. 2018 pii: S0304-3835(18)30652-9
Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1.Namba M, Hattori N, Hamada H, Yamaguchi K, Okamoto Y, Nakashima T, Masuda T, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Kohno N
Mol Clin Oncol. 2018 Nov;9(5):539-544
Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility study.Masuda T, Watanabe M, Fujitaka K, Hamai K, Ishikawa N, Doi M, Kitaguchi S, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Senoo T, Iwamoto H, Hamada H, Hattori N
Exp Ther Med. 2018;16:3070-3076
Plasminogen activator inhibitor-1 serves an important role in radiation-induced pulmonary fibrosis.Shioya S, Masuda T, Senoo T, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N
In Vivo. 2018;32:1155-1160
Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study.Yamaguchi K, Masuda T, Fujitaka K, Miwata K, Sakamoto S, Horimasu Y, Hamai K, Miyamoto S, Nakashima T, Okamoto Y, Iwamoto H, Ishikawa N, Miyata Y, Okada M, Hamada H, Hattori N
Mol Ther Nucleic Acids. 2018;12:698-706
Intratracheal Administration of siRNA Dry Powder Targeting Vascular Endothelial Growth Factor Inhibits Lung Tumor Growth in Mice.Miwata K, Okamoto H, Nakashima T, Ihara D, Horimasu Y, Masuda T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Shibata A, Ito T, Okuda T, Hattori N
Eur Respir J. 2018. pii: 1701610
Aminopeptidase N/CD13 as a Potential Therapeutic Target in Malignant Pleural Mesothelioma.Otsuki T, Nakashima T, Hamada H, Takayama Y, Akita S, Masuda T, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Miyake M, Kohno N, Okada M, Hattori N
Cancer Chemother Pharmacol. 2018;81:131-139
The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancerMasuda T, Hirano C, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N
2017
Oncotarget. 2017;8:94382-92
AGER rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinomaYamaguchi K, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N
BMC Med Genet. 2017;18:88
Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targetsHorimasu Y, Ishikawa N, Taniwaki M, Yamaguchi K, Hamai K, Iwamoto H, Ohshimo S, Hamada H, Hattori N, Okada M, Arihiro K, Ohtsuki Y, Kohno N
BMC Cancer. 2017;17:263
MUC1 in lung adenocarcinoma: cross-sectional genetic and serological studyHorimasu Y, Ishikawa N, Tanaka S, Hirano C, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N, Kohno N
Clin Lung Cancer. 2017 in press
Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer.Sakamoto S, Yamada T, Terazaki Y, Yoshiyama K, Sugawara S, Takamori S, Matsueda S, Shichijo S, Yamada A, Noguchi M, Itoh K, Hattori N, Kohno N, Sasada T
Respirology. 2017;22:965-71
AGER gene polymorphisms and soluble receptor for advanced glycation end product in patients with idiopathic pulmonary fibrosisYamaguchi K, Iwamoto H, Horimasu Y, Ohshimo S, Fujitaka K, Hamada H, Mazur W, Kohno N, Hattori N
Cancer Sci. 2017;108:598-603
Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ alleleSakamoto S, Matsueda S, Takamori S, Toh U, Noguchi M, Yutani S, Yamada A, Shichijo S, Yamada T, Suekane S, Kawano K, Naitou M, Sasada T, Hattori N, Kohno N, Itoh K
Free Radic Biol Med. 2017;106:1-9
Suplatast tosilate protects the lung against hyperoxic lung injury by scavenging hydroxyl radicalsFukuhara K, Nakashima T, Abe M, Masuda T, Hamada H, Iwamoto H, Fujitaka K, Kohno N, Hattori N
2016
Respir Med 2017;123:105-109
FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosisHirano C, Ohshimo S, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, Hattori N, Shime N, Bonella F, Guzman J, Costabel U, Kohno N
Respirology. 2017;22:86-92
Clinically remitted childhood asthma is associated with airflow obstruction in middle-aged adultsOmori K, Iwamoto H, Yamane T, Nakashima T, Haruta Y, Hattori N, Yokoyama A, Kohno N
Int J Chron Obstruct Pulmon Dis. 2016;11:2457-2465
Characterization of sputum biomarkers for asthma-COPD overlap syndromeGao J, Iwamoto H, Koskela J, Alenius H, Hattori N, Kohno N, Laitinen T, Mazur W, Pulkkinen V
PLoS One. 2016;11:e0162672
Sputum Leucine-Rich Alpha-2 Glycoprotein as a Marker of Airway Inflammation in AsthmaHonda H, Fujimoto M, Miyamoto S, Ishikawa N, Serada S, Hattori N, Nomura S, Kohno N, Yokoyama A, Naka T
Occup Environ Med. in press
Mustard gas exposure and mortality among retired workers at a poisonous gas factory in Japan: a 57-year follow-up cohort studyMukaida K, Hattori N, Iwamoto H, Onari Y, Nishimura Y, Kondoh K, Akita T, Tanaka J, Kohno N
Respirology. in press
Clinically remitted childhood asthma is associated with airflow obstruction in middle-aged adultsOmori K, Iwamoto H, Yamane T, Nakashima T, Haruta Y, Hattori N, Yokoyama A, Kohno N
Dis Markers. 2016;2016:4759040
Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary FibrosisHamai K, Iwamoto H, Ishikawa N, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N, Kohno N
Cancer Res. 2016;76:3285-94
Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural MesotheliomaTakayama Y, Hattori N, Hamada H, Masuda T, Omori K, Akita S, Iwamoto H, Fujitaka K, Kohno N
Inhal Toxicol. 2016;28:343-8
Long-term pulmonary complications of chemical weapons exposure in former poison gas factory workersNishimura Y, Iwamoto H, Ishikawa N, Hattori N, Horimasu Y, Ohshimo S, Fujitaka K, Kondo K, Hamada H, Awai K, Kohno N
PLoS One. 2016; 11:e0148969
Inhibition of Plasminogen Activator Inhibitor-1 Attenuates Transforming Growth Factor-β-Dependent Epithelial Mesenchymal Transition and Differentiation of Fibroblasts to MyofibroblastsOmori K, Hattori N, Senoo T, Takayama Y, Masuda T, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Kohno N
2015
BMC Infect Dis. 2015; 15:426
Clinical characteristics and risk factors of enterococcal infections in Nagasaki, Japan: a retrospective studyKajihara T, Nakamura S, Iwanaga N, Oshima K, Takazono T, Miyazaki T, Izumikawa K, Yanagihara K, Kohno N, Kohno S
Hum Vaccin Immunother. 2015; 11:2784-9
Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccinationSakamoto S, Yoshitomi M, Yutani S, Terazaki Y, Yoshiyama K, Ioji T, Matsueda S, Yamada A, Takamori S, Itoh K, Hattori N, Kohno N, Sasada T
Cancer Sci. 2015; 106:1257-63
Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 alleleSakamoto S, Matsueda S, Takamori S, Toh U, Noguchi M, Yutani S, Yamada A, Shichijo S, Yamada T, Suekane S, Kawano K, Sasada T, Hattori N, Kohno N, Itoh K
Pharm Res. 2015; 32:3877-85
Histological Quantification of Gene Silencing by Intratracheal Administration of Dry Powdered Small-Interfering RNA/Chitosan Complexes in the Murine LungIhara D, Hattori N, Horimasu Y, Masuda T, Nakashima T, Senoo T, Iwamoto H, Fujitaka K, Okamoto H, Kohno N
Cancer Sci. 2015l; 106:921-8
MT95-4, a fully humanized antibody raised against aminopeptidase N, reduces tumor progression in a mouse modeAkita S, Hattori N, Masuda T, Horimasu Y, Nakashima T, Iwamoto H, Fujitaka K, Miyake M, Kohno N
Int J Chron Obstruct Pulmon Dis. 2015; 10:185-92
Airway inflammation in Japanese COPD patients compared with smoking and nonsmoking controlsIshikawa N, Hattori N, Kohno N, Kobayashi A, Hayamizu T, Johnson M
Respirology. 2015; 20:439-44
MUC5B promoter polymorphism in Japanese patients with idiopathic pulmonary fibrosisHorimasu Y, Ohshimo S, Bonella F, Tanaka S, Ishikawa N, Hattori N, Kohno N, Guzman J, Costabel U
Respirology. 2015; 20:87-94
Effect of increasing respiratory rate on airway resistance and reactance in COPD patientsNakagawa M, Hattori N, Haruta Y, Sugiyama A, Iwamoto H, Ishikawa N, Fujitaka K, Murai H, Tanaka J, Kohno N
2014
Respir Med. 2014; 108:1031-9
Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosisOhshimo S, Ishikawa N, Horimasu Y, Hattori N, Hirohashi N, Tanigawa K, Kohno N, Bonella F, Guzman J, Costabel U
BMC Med Genet. 2014;15:4
Differences in serum SP-D levels between German and Japanese subjects are associated with SFTPD gene polymorphismsHorimasu Y, Hattori N, Ishikawa N, Tanaka S, Bonella F, Ohshimo S, Guzman J, Costabel U, Kohno N
2013
Mol Cancer Res. 2013; 11:937-51
RASEF is a novel diagnostic biomarker and a therapeutic target for lung cancer.Oshita H, Nishino R, Takano A, Fujitomo T, Aragaki M, Kato T, Akiyama H, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y.
Respir Med. 2013; 107:875-82
Characteristics of inspiratory and expiratory reactance in interstitial lung diseaseSugiyama A, Hattori N, Haruta Y, Nakamura I, Nakagawa M, Miyamoto S, Onari Y, Iwamoto H, Ishikawa N, Fujitaka K, Murai H, Kohno N
Mol Cancer Ther. 2013; 12:2378-88
SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis.Masuda T, Hattori N, Senoo T, Akita S, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Kohno N
2012
Hiroshima J Med Sci 2012; 61:29-36
Cigarette smoking decreases dynamic inspiratory capacity during maximal exercise in patients with type 2 diabetesKitahara Y, Hattori N, Yokoyama A, Yamane K, Sekikawa K, Inamizu T, Kohno N.
Int J Cancer. 2012; 130:377-87
Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected non-small cell lung cancer.Tanaka S, Hattori N, Ishikawa N, Shoda H, Takano A, Nishino R, Okada M, Arihiro K, Inai K, Hamada H, Yokoyama A, Kohno N.
Pathobiology 2012; 79:24-33
Interferon (alpha, Beta and omega) receptor 2 is a prognostic biomarker for lung cancer.Tanaka S, Hattori N, Ishikawa N, Horimasu Y, Deguchi N, Takano A, Tomoda Y, Yoshioka K, Fujitaka K, Arihiro K, Okada M, Yokoyama A, Kohno N.
Respir Med 2012; 106:1756-64
Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels.Horimasu Y, Hattori N, Ishikawa N, Kawase S, Tanaka S, Yoshioka K, Yokoyama A, Kohno N, Bonella F, Guzman J, Ohshimo S, Costabel U.
Respir Investig. 2012; 50:3-13
Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases.Ishikawa N, Hattori N, Yokoyama A, Kohno N.
Immunol Allergy Clin North Am 2012; 32:537-56
Hypersensitivity pneumonitis.Ohshimo S, Bonella F, Guzman J, Costabel U.
2011
Oncol Lett. 2011; 2:167-170
Phase I study of docetaxel plus S-1 combination chemotherapy for recurrent non-small cell lung cancerFujitaka K, Hattori N, Senoo T, Iwamoto H, Ohshimo S, Kanehara M, Ishikawa N, Haruta Y, Murai H, Kohno N
Am J Epidemiol. 2011; 173:659-66
Effect of mustard gas exposure on incidence of lung cancer: a longitudinal studyDoi M, Hattori N, Yokoyama A, Onari Y, Kanehara M, Masuda K, Tonda T, Ohtaki M, Kohno N
Respir Res. 2011; 12:32
KL-6 concentration in pulmonary epithelial lining fluid is a useful prognostic indicator in patients with acute respiratory distress syndromeKondo T, Hattori N, Ishikawa N, Murai H, Haruta Y, Hirohashi N, Tanigawa K, Kohno N
Phytomedicine. 2011; 18:625-9
A pilot study of the multiherb Kampo medicine bakumondoto for cough in patients with chronic obstructive pulmonary diseaseMukaida K, Hattori N, Kondo K, Morita N, Murakami I, Haruta Y, Yokoyama A, Kohno N
J Asthma. 2011; 48:907-13
Association of airway inflammation with asthma control level evaluated by the asthma control testShiota N, Yokoyama A, Haruta Y, Hattori N, Kohno N
Chest. 2011; 139:296-304
Mucins carrying selectin ligands as predictive biomarkers of disseminated intravascular coagulation complication in ARDSNakashima T, Yokoyama A, Inata J, Ishikawa N, Haruta Y, Hattori N, Kohno N
Allergol Int. 2011; 60:299-304
Chronic hepatitis C virus infection is associated with more severe asthmaNakashima T, Yokoyama A, Ohnishi H, Yamasaki M, Shiode M, Haruta Y, Hattori N, Hozawa S, Yamakido H, Kohno N
Am J Physiol Lung Cell Mol Physiol. 2011; 301:L908-16
Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 attenuates allergic asthma in miceMiyamoto S, Hattori N, Senoo T, Onari Y, Iwamoto H, Kanehara M, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Yokoyama A, Kohno N
Respir Res. 2011; 12:97
Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung diseaseKawase S, Hattori N, Ishikawa N, Horimasu Y, Fujitaka K, Furonaka O, Isobe T, Miyoshi S, Hamada H, Yamane T, Yokoyama A, Kohno N
Cancer Chemother Pharmacol. 2011; 67:1465-9
Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapyMasuda T, Hattori N, Hamada A, Iwamoto H, Ohshimo S, Kanehara M, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Kohno N
Respiration. 2011; 82:10-8
Levels of surfactant proteins A and D and KL-6 are elevated in the induced sputum of chronic obstructive pulmonary disease patients: a sequential sputum analysisIshikawa N, Hattori N, Tanaka S, Horimasu Y, Haruta Y, Yokoyama A, Kohno N, Kinnula VL
Clin Cancer Res. 2011; 17:6272-86
Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancerNishino R, Takano A, Oshita H, Ishikawa N, Akiyama H, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y
Clin Cancer Res. 2011; 17:7712-22
Chondrolectin is a novel diagnostic biomarker and a therapeutic target for lung cancerMasuda K, Takano A, Oshita H, Akiyama H, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y
Hiroshima J Med Sci 2011; 60:7-9
Regression of a primary pulmonary adenocarcinoma after zoledronic acid monotherapyagao S, Hattori N, Fujitaka K, Iwamoto H, Ohshimo S, Kanehara M, Ishikawa N, Haruta Y, Murai H, Kohno N
